ELISA-based hyaluronidase activity detection method

Through the detection method based on ELISA, the matrix interference problem of the prior art when detecting hyaluronidase activity in plasma and other samples is solved, and accurate quantity detection under the presence of interference is achieved. It is suitable for a variety of dose scenarios and is used for medicine Generation kinetics research provides effective detection methods.

CN118937674APending Publication Date: 2024-11-12湖北天勤鑫圣生物科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411136825.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing turbidity method and ultraviolet spectrophotometry are susceptible to matrix interference when detecting the activity of hyaluronidase in human or animal fluids such as plasma, resulting in inaccurate measurement results and complex operation, making it difficult to apply to actual samples. Pharmacokinetics study.

Method used

Using an ELISA-based detection method, the enzyme-label well plate was treated by coating solution and blocking solution, the samples to be tested were treated with gradient diluted hyaluronidase standards and assay buffer, and incubated with streptavidin secondary antibody and The color reaction was used to determine the absorbance value to quantitatively detect hyaluronidase activity, and a standard curve was drawn for quantitative analysis.

Benefits of technology

This method can accurately and sensitively detect hyaluronidase activity in the presence of matrix interference, which is simple to operate and is suitable for a variety of dose scenarios, providing reference for the pharmacokinetic research of subcutaneous preparation drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937674A_ABST
    Figure CN118937674A_ABST
Patent Text Reader

Abstract

The invention discloses a hyaluronidase activity detection method based on ELISA, and relates to the technical field of enzyme activity detection. The method comprises the following steps: coating and sealing an enzyme label pore plate by using a coating solution and a sealing solution; the coating solution is prepared from acetic acid, hyaluronic acid biotin sodium salt and a CBS buffer solution; preparing a hyaluronidase standard substance working solution by using the analysis solution; diluting a to-be-detected sample by using the analysis buffer solution to prepare a to-be-detected working solution; the analysis solution is an ammonium formate aqueous solution with the pH value of 4.5-7.5; adding a standard substance working solution and a to-be-detected working solution into the enzyme-labeled pore plate, and incubating; adding a second antibody, and incubating; finally, sequentially adding a developing solution and a stop solution, and measuring an absorbance value; drawing a standard curve by using the OD450 value of the standard substance working solution; and quantifying the hyaluronidase activity in the to-be-detected sample according to the OD450 value of the to-be-detected working solution and the standard curve.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of enzyme activity detection, and in particular to a method for detecting hyaluronidase activity based on ELISA. Background Art

[0002] Recombinant human hyaluronidase (rHuPH20) is a hot topic in the current drug delivery field, and its application scope is mainly subcutaneous administration and tumor treatment. Subcutaneous injection of monoclonal antibody drugs with rHuPH20 added is highly similar to intravenous injection in terms of pharmacokinetics, efficacy and safety, but the immunogenicity is lower than that of intravenous injection. Subcutaneous injection is a new way of administration for monoclonal antibody drugs, and improving and perfecting its quality control methods is an important part of the release and supervision of monoclonal antibody drugs. At present, rHuPH20 has been approved by the FDA for subcutaneous injection. Its simultaneous administration with cetuximab can accelerate the absorption of the drug; and rHuPH20 activity is an important release detection indicator for the quality control of such monoclonal antibody drugs. In current experimental studies, the commonly used rHuPH20 activity detection methods are turbidity and ultraviolet spectrophotometry.

[0003] Turbidimetry is a relatively classic and commonly used method. It is also a method included in the Chinese Pharmacopoeia and the United States Pharmacopoeia, and is suitable for the determination of various hyaluronidase activities. The detection principle of the turbidity method is that hyaluronic acid can combine with acidified serum to form a precipitate; after the reaction of hyaluronic acid with rHuPH20, acidified serum is added to precipitate the undigested hyaluronic acid; then the turbidity is measured at 640 nm to obtain the hyaluronidase activity. However, hyaluronidase is a family of enzymes that are widely present in microorganisms and animal tissues and specifically degrade hyaluronic acid. It is an endogenous substance. In pharmacokinetic studies, there is often interference from endogenous hyaluronidase in plasma samples, resulting in the measured data results not reflecting the actual concentration of hyaluronidase administration. Therefore, the turbidity method is only suitable for test subjects without matrix interference, such as in vitro studies, and is not suitable for determining the hyaluronidase activity in actual samples such as plasma. The standard curve points drawn by the turbidity method exceed 10, so the operation is also more complicated. The principle of ultraviolet spectrophotometry is based on the fact that the double bonds in the degradation products have a maximum absorption value under 232 nm ultraviolet light. It is only used to determine the activity of specific hyaluronan lyases and its scope of application has obvious limitations.

[0004] Since the study of hyaluronidase metabolism in vivo is of vital importance, how to provide a method for detecting hyaluronidase activity that can eliminate the interference of sample matrix for other human / animal body fluids such as plasma, or other actual samples that may have matrix interference, has very high practical application value. Summary of the invention

[0005] The present invention provides a method for detecting hyaluronidase activity based on ELISA in view of the deficiencies of the above-mentioned various rHuPH20 activity detection methods. This method is based on Elisa technology, and measures the hyaluronidase activity in samples with matrix interference such as human or animal sources. It is easy to operate, not interfered by the matrix, and can be accurately and sensitively quantified, providing a reference for the in vivo pharmacokinetic study of hyaluronidase in subcutaneous preparations. It is specifically achieved by the following techniques.

[0006] A method for detecting hyaluronidase activity based on ELISA, comprising the following steps: Using a coating solution and a blocking solution to sequentially coat and block each well of the enzyme-labeled well plate; the coating solution is prepared using acetic acid, hyaluronic acid biotin sodium salt and CBS buffer; Use analytical solution to gradient dilute the hyaluronidase standard to prepare several standard working solutions; use analytical buffer to dilute the sample to be tested to prepare the working solution to be tested; the analytical solution is an ammonium formate aqueous solution with a pH value of 4.5-7.5; Adding a certain amount of the standard working solution and the working solution to be tested to each well of the ELISA well plate, incubating for the first time, and washing the plate; Add secondary antibody to each well, incubate for the second time, wash the plate; add colorimetric solution for color development; add stop solution and measure the absorbance value OD 450 ; The OD values ​​corresponding to the standard working solutions were calculated by gradient dilution. 450 Draw a standard curve according to the OD value of the working solution to be tested. 450 The hyaluronidase activity in the sample to be tested is quantified using the value and the standard curve.

[0007] Furthermore, the pH value of the coating solution is 2.4-3.0.

[0008] Furthermore, the concentration of hyaluronan-biotin sodium salt in the coating solution is 10-100 μg / mL.

[0009] Furthermore, the coating treatment is carried out at 2-8°C for 16-72 h.

[0010] Furthermore, the sealing treatment is performed at room temperature for 1-2 h.

[0011] Furthermore, the first incubation is performed at 37° C. for 50-70 min.

[0012] Furthermore, the secondary antibody is a streptavidin secondary antibody with a concentration of 1:(10000-20000).

[0013] Furthermore, the second incubation is performed at room temperature for 25-35 min.

[0014] Furthermore, a four-parameter method was used for curve fitting with a weight factor of 1.

[0015] Compared with the prior art, the advantages of the present invention are as follows: the present invention provides a set of ELISA-based hyaluronidase activity detection methods, which are easy to operate and can accurately and sensitively quantitatively detect the activity of hyaluronidase in drugs in samples under unfavorable conditions such as matrix interference in samples such as blood. It is suitable for a variety of different linear range quantitative intervals and various dosage administration scenarios, providing a reference for the in vivo pharmacokinetics study of hyaluronidase in subcutaneous preparations. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is the standard curve obtained for the test group of Test Example 1.

[0017] Figure 2 The standard curve is obtained by selecting coating solutions with different concentrations of hyaluronan-biotin sodium salt.

[0018] Figure 3 The standard curve was obtained by selecting analytical buffers with different pH values.

[0019] Figure 4 The standard curve was obtained by selecting different SA-HRP secondary antibody concentrations. DETAILED DESCRIPTION

[0020] The technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0021] In some embodiments of the present invention, the provided ELISA-based hyaluronidase activity detection method comprises the following steps: Step 1: Use coating solution and blocking solution to coat and block each well of the enzyme-labeled well plate in turn; the coating solution is prepared using acetic acid, hyaluronan biotinsodium salt stock and CBS buffer.

[0022] Use the analytical solution to gradient dilute the hyaluronidase standard to prepare several standard working solutions.

[0023] The sample to be tested is diluted with an analytical buffer to prepare a working solution to be tested; the analytical solution is an ammonium formate aqueous solution with a pH value of 4.5-7.5.

[0024] The above-mentioned processes of coating and blocking the ELISA well plate, as well as the preparation of various reagents, can generally be carried out simultaneously.

[0025] Step 2: In order to draw and obtain a standard curve, add some of the standard working solution to each well of the ELISA plate. In addition, add the working solution to be tested to other wells of the ELISA plate. Perform the first incubation for each well and wash the plate.

[0026] Step 3: Add secondary antibody to each well, incubate for the second time, and wash the plate.

[0027] Step 4: Add color developing solution for color development; finally add stop solution and measure the absorbance value OD 450 .

[0028] Step 5: Use the OD values ​​corresponding to the gradient dilutions of the standard working solutions 450 Draw a standard curve according to the OD value of the working solution to be tested. 450 The hyaluronidase activity in the sample to be tested is quantified using the value and the standard curve.

[0029] In some embodiments of the present invention, the pH value of the coating solution is 2.4-3.0.

[0030] In some embodiments of the present invention, the concentration of hyaluronic acid biotin sodium salt in the coating solution is 10-100 μg / mL In some embodiments of the present invention, the ELISA plate is coated at 2-8° C. for 16-72 h.

[0031] In some embodiments of the present invention, the ELISA plate is sealed at room temperature for 1-2 h.

[0032] In some embodiments of the present invention, the first incubation is performed at 37° C. for 50-70 min.

[0033] In some embodiments of the present invention, the second incubation is performed at room temperature for 25-35 min.

[0034] The test objects in the following test examples are blood samples from SD rats, which are obtained by subcutaneous injection of rHuPH20 test sample through the back skin of SD rats, once a week for 4 consecutive weeks, and a total of 5 times. Blood is collected from the jugular vein and EDTA•K2 is used. Collect samples in anticoagulant tubes and centrifuge at 2000 g for 10 min at 2-8°C within 2 hours after sample collection. Separate plasma and freeze at -70°C or below for testing.

[0035] Experimental Example 1: Effect of coating buffer on hyaluronidase activity detection This test case is divided into an experimental group and a control group.

[0036] The test group provided a method for detecting hyaluronidase activity, the steps of which are as follows: (1) Coating and blocking the ELISA plate: Take 300 mM Acetic Acid solution and dilute 10 mg / mL Hyaluronan biotin sodium salt Stock (CBS) to 100 µg / mL to prepare the coating solution; add 100 µL of the coating solution to each well of the ELISA plate and coat at 4°C for 24 h; perform the coating. Discard the coating solution in the wells, add 300 µL of washing solution (0.05% PBST) to each well and wash the plate three times; after the last wash, pat dry the remaining washing solution on absorbent paper. Then add 300 µL of blocking solution (1% BSA-PBST) to each well of the ELISA plate and block at room temperature for 2 h. Discard the blocking solution, add 300 μL of washing solution to each well and wash four times. After the last wash, pat dry the remaining washing solution on absorbent paper.

[0037] Prepare standard working solution: take rHuPH20 standard (purchased from Halozyme, product number: H841), and use dilution buffer (1% BSA-PBST, pH 7.4) to dilute the rHuPH20 standard into 11 standard working solutions with concentration gradients of 10000, 4000.0, 1600.0, 640.0, 256.0, 102.4, 41.0, 16.4, 6.6, 2.6, and 1.0 U / mL.

[0038] Prepare analytical buffer: Weigh 0.63 g of Ammonium formate and add it to 100 mL of ultrapure water. Mix thoroughly to dissolve. Adjust the pH to 7.5 with 1 M hydrochloric acid to prepare 0.1 M ammonium formate buffer.

[0039] Preparation of the working solution to be tested: The plasma sample was diluted to the minimum multiple (MRD=50) with the analytical buffer.

[0040] (2) Add some of the standard working solution and the test working solution to each well of the ELISA plate and incubate at 37°C for 60 min. Discard the liquid in the ELISA plate, add 300 μL of cleaning solution to each well, and wash three times. After the last wash, pat dry the remaining washing solution on absorbent paper.

[0041] (3) Take 100 μL of SA-HRP secondary antibody (streptavidin secondary antibody) working solution (purchased from Thermo, catalog number: 21140, diluted 10,000 times with 1% BSA-PBST) and add it to each well. Incubate at room temperature for 30 min at a speed of about 300 rpm. Discard the liquid in the ELISA plate, add 300 μL of washing solution to each well, and wash 5 times. After the last wash, pat dry the remaining washing solution on absorbent paper.

[0042] (4) Add 100 μL TMB (color developing solution) to each well of the ELISA plate and incubate at room temperature in the dark for no more than 30 min. Add 100 μL Stop Solution to each well of the ELISA plate and read the absorbance value (OD) using an ELISA reader within 10 min. 450 .

[0043] (5) Save the data and use the Spectramax M3 microplate reader to measure the OD values ​​of the standard working solutions corresponding to the 11 concentration gradients. 450 , the four-parameter method is used for curve fitting, and the weight factor is 1.

[0044] The method for detecting hyaluronidase activity used in the control group was basically the same as that in the above experimental group, with the only difference being that conventional ELISA coating solution was used to replace the coating solution in the above experimental group method; the preparation method of conventional ELISA coating solution was as follows: Hyaluronan biotin sodium salt Stock (10 mg / mL) was diluted to 100 µg / mL using 0.5 M CBS for coating.

[0045] like Figure 1 As shown, the standard curve equation obtained by the test group is: y=D+(AD) / [1+(x / C)B], A=2.348, B=1.015, C=251.3, D=0.130, R 2 =0.997. The standard curve equation obtained by the method of the test group can be used for quantitative detection of hyaluronidase activity in the sample to be tested. In contrast, when the coating solution of the test group is replaced by the conventional ELISA coating solution, the standard curve obtained has no gradient and cannot be tested accordingly.

[0046] Experimental Example 2: Effect of the Concentration of Sodium Hyaluronan-Biotin in the Coating Solution on the Detection of Hyaluronidase Activity The hyaluronidase activity in the sample was detected by using a method substantially the same as that of the test group in Test Example 1. The difference was that 10 mg / mL Hyaluronan biotin sodium salt Stock (CBS) was diluted to 10, 20, 40, and 100.0 µg / mL using 300 mM acetic acid solution for coating.

[0047] The results are as follows Figure 2 As shown in the figure, it can be seen that 10-100 μg / mL of biotin sodium salt coating concentration can be used in the experiment. 10 μg / mL was selected for subsequent experiments.

[0048] Experimental Example 3: Effect of different pH analytical buffers on hyaluronidase activity detection Since hyaluronidase is used as an excipient in monoclonal antibody preparations and its content is relatively low, in order to accurately quantify the blood concentration of hyaluronidase in different dose groups in pharmacokinetics, the pH of the analytical buffer was adjusted to optimize the sensitivity of the method.

[0049] The hyaluronidase activity in the sample to be tested was detected by a method substantially the same as that of the test group of Test Example 1. The difference is that: the SA-HRP secondary antibody was diluted 20,000 times with 1% BSA-PBST; 0.63 g of Ammonium formate was weighed and added to 100 mL of ultrapure water, fully dissolved, mixed, and prepared into a 0.1 M ammonium formate buffer. The pH value was adjusted to different ranges with 1 M HCl to obtain analytical buffers with pH values ​​of 4.5, 5.0, 5.5, 6.0, 7.0, and 7.5, respectively.

[0050] The results are shown in Table 1 and Figure 3 As shown, analytical buffers at different pH values ​​can be used in different quantitative ranges (EC50 values ​​can reflect sensitivity), and can all be accurately quantified; among them, when the pH value of the analytical buffer is 4.5, the quantification reaches the best 0.5-20ng / mL.

[0051] Table 1 Specific standard curve parameters are as follows.

[0052]

[0053] Experimental Example 4: Effect of SA-HRP secondary antibody concentration on hyaluronidase activity detection The hyaluronidase activity in the test sample was detected by a method substantially the same as that of the test group of Test Example 1. The only difference was that the SA-HRP secondary antibody was diluted to 1:20000 and 1:10000 for incubation, and the pH of the analysis buffer was adjusted to 4.5 with 1M hydrochloric acid.

[0054] The results are as follows Figure 4As shown, it can be seen that the sensitivity of the two is not much different; the signal at 1:10000 is higher, so the concentration of 1:10000 was selected for subsequent experiments.

[0055] Test Example 5: Accuracy and Precision Verification and Selectivity Verification of Hyaluronidase Activity Detection Method This test example uses the same method as the test group of Test Example 1 to verify accuracy, precision and selectivity. The only difference is that the pH of the analytical buffer is 4.5 and the concentration of the SA-HRP secondary antibody is 1:10000.

[0056] 1. Accuracy and precision verification Methodological validation was performed according to the guidelines of "Guidelines for Validation of Quantitative Analysis Methods for Biological Samples" (China Pharmacopoeia Committee, Pharmacopoeia of the People's Republic of China 2020 edition) and Bioanalytical Method Validation and Study Sample Analysis. (ICH M10, May 2022).

[0057] The accuracy and precision verification method is: use PRP1 to prepare quality control samples with different active concentrations: ULOQ (20.000 U / mL), HQC (15.000 U / mL), MQC (3.000 U / mL), LQC (1.200 U / mL) and LLOQ (0.500 U / mL), and then use analytical buffer to dilute the quality control samples of each active concentration to the minimum required dilution (MRD=50). Each analytical batch contains a set of standard curve samples, three sets of quality control samples and a blank control. Each set of quality control samples includes five active concentration levels: ULOQ, HQC, MQC, LQC and LLOQ. The mean, standard deviation, %CV, %RE and %TE of the back-calculated concentration of each quality control sample are statistically analyzed.

[0058] Meet the following criteria: (1) Intra-batch accuracy: Calculate and report the average back-calculated activity concentration and %RE of each activity concentration level QCs. The average back-calculated activity concentration should satisfy the %RE within ± 20.0% (ULOQ and LLOQ within ± 25.0%). (2) Intra-batch precision: Calculate and report the average back-calculated activity concentration, standard deviation (SD), and %CV of QCs at each activity concentration level. The average back-calculated activity concentration should satisfy %CV ≤ 20.0% (≤ 25.0% for ULOQ and LLOQ); (3) Total error within the batch: Calculate and report the total error (Total Error) of QCs at each active concentration level. The total error should satisfy %TE ≤ 30.0% (≤ 40.0% for ULOQ and LLOQ).

[0059] (4) Inter-batch accuracy: Calculate and report the average back-calculated activity concentration and %RE of each activity concentration level QCs. The average back-calculated activity concentration should satisfy the %RE within ± 20.0% (within ± 25.0% for ULOQ and LLOQ); (5) Inter-batch precision: Calculate and report the average back-calculated activity concentration, standard deviation (SD) and %CV of QCs at each activity concentration level. The average back-calculated activity concentration should meet %CV ≤ 20.0% (≤ 25.0% for ULOQ and LLOQ); (6) Total Error between Batch: Calculate and report the total error (Total Error) of QCs at each active concentration level. The total error should satisfy %TE ≤ 30.0% (≤ 40.0% for ULOQ and LLOQ).

[0060] The accuracy and precision results are shown in Table 2 , indicating that 9 sets of quality control concentrations (LLOQ, LQC, MQC, HQC, and ULOQ levels) in 3 batches were all able to pass the validation.

[0061] Table 2 Summary of accuracy and precision batch quality control sample intra- and inter-batch results.

[0062]

[0063] 2. Selective Verification The selectivity validation method is as follows: 2% completely hemolyzed matrix is ​​added to the blank biological matrix to prepare the hemolyzed biological sample. The blank plasma of 10 individual animals (half male and half female) is used for selectivity validation, of which the plasma of 5 individual animals is the hemolyzed sample. The blank plasma is used to prepare two selective samples with active concentration levels of 15.000 U / mL (Sel-HQC) and 0.500 U / mL (Sel-LLOQ), and the blank plasma is used as the unspiked sample (Unspiked).

[0064] Acceptance criteria: For at least 80% of the individual sources, the %RE of the LLOQ of the target analyte standard sample should be within ±25.0% of the labeled value, and the %RE of the HQC should be within ±20.0% of the labeled value. The mean OD value of the unspiked samples of at least 80% of the individual sources should be above the LLOQ.

[0065] The results are shown in Table 3. It can be seen that 10 biological samples were analyzed at HQC, LLOQ, and Unspiked concentration levels by 10 SD rats, and 100% (10 / 10), 100% (10 / 10), and 100% (10 / 10) of the samples met the acceptance criteria at HQC, LLOQ, and Unspiked activity concentration levels, respectively. This shows that selectivity can be achieved in the presence of matrix interference.

[0066] Table 3 Selectivity verification results.

[0067]

[0068] The above specific embodiments describe the implementation of the present invention in detail, but the present invention is not limited to the specific details in the above embodiments. Within the scope of the claims and technical concept of the present invention, the technical solution of the present invention can be modified and changed in many simple ways, and these simple modifications all belong to the protection scope of the present invention.

Claims

1. A method for detecting hyaluronidase activity based on ELISA, characterized in that: The following steps are involved: Using a coating solution and a blocking solution to sequentially coat and block each well of the enzyme-labeled well plate; the coating solution is prepared using acetic acid, hyaluronic acid biotin sodium salt and CBS buffer; Use analytical solution to gradient dilute the hyaluronidase standard to prepare several standard working solutions; use analytical buffer to dilute the sample to be tested to prepare the working solution to be tested; the analytical solution is an ammonium formate aqueous solution with a pH value of 4.5-7.5; Adding a certain amount of the standard working solution and the working solution to be tested to each well of the ELISA well plate, incubating for the first time, and washing the plate; Add secondary antibody to each well, incubate for a second time, and wash the plate; Add color developing solution to develop color; add stop solution and measure the absorbance value OD 450 ; The OD values ​​corresponding to the working solutions of the standard substances were calculated by gradient dilution. 450 Draw the standard curve with the values; According to the OD corresponding to the working solution to be tested 450 The hyaluronidase activity in the sample to be tested is quantified using the value and the standard curve.

2. The method for detecting hyaluronidase activity based on ELISA according to claim 1, characterized in that: The pH value of the coating solution is 2.4-3.

0.

3. The method for detecting hyaluronidase activity based on ELISA according to claim 1, characterized in that: The concentration of hyaluronan-biotin sodium salt in the coating solution is 10-100 μg / mL.

4. The method for detecting hyaluronidase activity based on ELISA according to claim 1, characterized in that: The coating treatment method is 2-8°C coating for 16-72 hours.

5. The method for detecting hyaluronidase activity based on ELISA according to claim 1, characterized in that: The sealing treatment is performed at room temperature for 1-2 h.

6. The method for detecting hyaluronidase activity based on ELISA according to claim 1, characterized in that: The first incubation is performed at 37° C. for 50-70 min.

7. The method for detecting hyaluronidase activity based on ELISA according to claim 1, characterized in that: The secondary antibody is streptavidin secondary antibody, and the concentration is 1:(10000-20000).

8. The method for detecting hyaluronidase activity based on ELISA according to claim 1, characterized in that: The second incubation is performed at room temperature for 25-35 min.

9. The method for detecting hyaluronidase activity based on ELISA according to claim 1, characterized in that: The four-parameter method was used for curve fitting with a weight factor of 1.